Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allarity Therapeutics (ALLR) Common Equity (2024 - 2025)

Allarity Therapeutics' Common Equity history spans 2 years, with the latest figure at $9.8 million for Q4 2025.

  • For Q4 2025, Common Equity fell 16.79% year-over-year to $9.8 million; the TTM value through Dec 2025 reached $9.8 million, down 16.79%, while the annual FY2025 figure was $9.8 million, 16.79% down from the prior year.
  • Common Equity reached $9.8 million in Q4 2025 per ALLR's latest filing, down from $12.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $19.8 million in Q2 2024 to a low of -$6.5 million in Q1 2024.